Example deliverable — specialty pharma brand
An independent, publicly-sourced assessment of a specialty pharma brand's digital patient experience: brand.com, enrollment flows, financial assistance, and support programs.
Too many owners. Too expensive. Too slow.
60+ screens. 5+ documents. Publicly sourced.
Here's what we found.
Fax-first Start Form in 2026. No digital portal. Triple signature requirement creates unnecessary friction.
Zero caregiver-specific resources for a disease primarily affecting young people. One of the largest gaps in the experience.
97% of commercially insured patients pay $0/month. Clear, specific messaging. Best dimension in the assessment.
Information architecture reflects brand thinking, not patient journeys. No guided pathways for newly diagnosed.
Each dimension scored on a 1-10 scale based on observable, evidence-based criteria
Ranked by impact and feasibility
Replace the fax-based Start Form with digital enrollment and e-consent. Combine with streamlined access to financial assistance online. The triple-signature paper process is the biggest friction point between prescription and first dose.
Restructure brand.com around patient stages (Newly Diagnosed, Considering Treatment, On Treatment) instead of brand-centric sections. Capture patients at their highest-need moment.
FA primarily affects young people. Parents, partners, and siblings are central to treatment decisions. the brand currently has zero caregiver-specific content, yet this audience drives much of the research and enrollment activity.
Here's what you get.
This Digital Patient Experience Snapshot was produced by Genflare using publicly available information only. No proprietary data, internal systems, or client participation was required.
Genflare is an AI advisory and services firm focused exclusively on life sciences. We help commercial teams see their patient experience the way patients actually see it, and fix what's broken.
All scoring reflects Genflare's assessment methodology based on observable, evidence-based criteria. Each dimension is evaluated on a 1-10 scale across defined attributes specific to the therapeutic area.